Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the minimal residual disease-negativity rate after administration of the combination of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab as induction and consolidation therapy in an intensive program in newly diagnosed standard risk multiple myeloma patients.

For the induction therapy, each patient received 6 cycles of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab, then peripheral blood stem cell harvest, intensification with autologous stem cell transplantation, consolidation therapy and maintenance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109

Myeloma, Multiple

ACTIVE_NOT_RECRUITING PHASE2

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

NCT02897830

Multiple Myeloma

TERMINATED PHASE2

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

NCT03433001

Relapsed and/or Refractory Multiple Myeloma

COMPLETED

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

NCT03606577

Multiple Myeloma

ACTIVE_NOT_RECRUITING PHASE2

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208

Multiple Myeloma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II, multicenter, non-randomized, open-label study to evaluate the safety and efficacy of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in patients with newly diagnosed multiple myeloma.

The patient population will consist of adult men and women ≤ 65 years, who have a confirmed diagnosis of standard risk multiple myeloma, who meet eligibility criteria.

Treatment periods will be defined as 21-day cycles for induction, and 28-day cycles for consolidation, and maintenance. Patients will be seen at regular treatment cycle intervals while they are participating in the study.

Patients will be assessed for disease response and progression according to the International Myeloma Working Group criteria at each cycle during induction and consolidation and every other cycle during maintenance.

Eastern Cooperative Oncology Group performance status, adverse events, laboratory values, and vital sign measurements will be collected and assessed to evaluate the safety of therapy throughout the study.

Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events. Patients will attend an End of Treatment visit after receiving their last dose of study drug and will continue to be followed for other follow-up assessments specified in the Schedule of events.

All patients will be followed for survival after progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

four drugs combination

21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab

Group Type EXPERIMENTAL

Ixazomib

Intervention Type DRUG

21-day cycles induction and 28-day cycles consolidation

Lenalidomide

Intervention Type DRUG

21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy

Dexamethasone

Intervention Type DRUG

21-day cycles induction and 28-day cycles consolidation

Daratumumab

Intervention Type DRUG

21-day cycles induction and 28-day cycles consolidation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ixazomib

21-day cycles induction and 28-day cycles consolidation

Intervention Type DRUG

Lenalidomide

21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy

Intervention Type DRUG

Dexamethasone

21-day cycles induction and 28-day cycles consolidation

Intervention Type DRUG

Daratumumab

21-day cycles induction and 28-day cycles consolidation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* De novo symptomatic myeloma on the International Myeloma Working Group Diagnostic Criteria for the Diagnosis of Multiple Myeloma
* Measurable disease requiring systemic therapy defined by serum M-component ≥ 10g/l or urine M-component ≥ 200 mg/24h or involved free light level ≥ 100 mg/l
* Eastern Cooperative Oncology Group performance status 0, 1 or 2
* Eligible to high dose therapy

Exclusion Criteria

* Previously treated with any systemic therapy for multiple myeloma
* Clinical signs of central nervous system involvement
* Renal insufficiency defined as estimated Glomerular Filtration Rate lower or equal to 40 ml/min/1.73 m2
* Hepatic impairment defined as aspartate transminase or alanine transaminase greater or equal to 3 x upper limit of normal, or Total bilirubin greater or equal to 3 x upper limit of normal
* Platelet count \< 75,000 per µL
* Absolute neutrophil count ≤ 1,000 cells/mm3
* Evidence of current uncontrolled cardiovascular conditions
* Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening
* Infection requiring systemic antibiotic therapy or other serious infection within 14 days before first dose of study drug
* Grade 3 or higher peripheral neuropathy, or grade 2 with pain, on clinical examination during the screening period
* Known or suspected chronic obstructive pulmonary disease with a Forced Expiratory Volume in 1 second \< 50% of predicted normal
* Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort within 14 days before initiation of the study drug

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michel ATTAL, MD

Role: STUDY_DIRECTOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.